An observational study in Dementia and Mild Cognitive Impairment (MCI), sponsored by IRCCS Centro Neurolesi Bonino Pulejo. Recruiting at 1 site in Italy. Open to participants aged 50 Years to 86 Years. Per ClinicalTrials.gov, last updated 2025-12-17.
Sponsored by IRCCS Centro Neurolesi Bonino Pulejo · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 92 studies in Dementia with a site in Italy — 37 open to participants now, 44 under way, 7 of them phase 3. Dementia · Italy.
Among the 92 studies in Dementia with a site in Italy, this one is the 20th largest by planned enrollment of the 26 observational ones that give a count, is one of 9 that started in 2025, is one of 26 observational ones, reaches primary completion later than 20 of the 43 other live ones, and was the 82nd registered.
2,377 studies on the registry are indexed under Dementia; 572 are open to participants now.
Browse Dementia studies →37 of the 92 studies in Dementia with a site in Italy are open now. Recruiting first, the newest first:
Giovanna Zamboni · Sites in Italy
Ages 40+
Stichting International Registry for Alzheimer's Disease and other Dementias Foundation · Sites in Italy, Australia, Austria and 14 more countries
Ages 18+
Exciva GmbH · Sites in Italy, United States, Canada and 6 more countries
Ages 55–90
Fondazione Don Carlo Gnocchi ETS · Sites in Italy
Ages 45+
Fondazione Don Carlo Gnocchi ETS · Sites in Italy
Ages 65+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 382 Dementia studies recruiting now, 242 (63%) set no upper age limit and 25 (7%) stop at 75 or younger; 15 take children under 18; 163 take healthy volunteers.
This study: 50 Years to 86 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
92 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 18 · Phase 3 25 · Phase 4 1
First in 2001; this study’s year is marked. 9 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 151 is below the median of 252 across 554 observational studies indexed under Dementia.
Median enrollment 280 across the 66 interventional studies, 283 across the 26 observational. Of the 39 that completed or were terminated, 12 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 92 have an industry lead sponsor. The 10 most frequent:
IRCCS Centro Neurolesi Bonino Pulejo is the lead sponsor of 67 studies on the registry; 30 are open to participants now.
IRCCS Centro Neurolesi Bonino Pulejo has 4 studies filed under Dementia — fewer than ten, so there is no comparison to draw.
12 of the studies in Dementia with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07404410Giovanna ZamboniRobotic Technologies for APATHy in Dementia: a Randomised Controlled Trial (RAPHAel) | 2026-11-30 |
| NCT07625241Istituto Superiore di SanitàCST+MST Intervention on People Living With Mild-to-moderate Dementia | 2026-12 |
| NCT07287410IRCCS Centro Neurolesi Bonino PulejoDementia and Mild Cognitive Impairment: Assessment of Cognitive Functioning, Functional Autonomy, and Neuropsychiatric Symptoms. | 2026-12-20 |
| NCT05794061Istituto Auxologico ItalianoAdvances in Neuropsychological Diagnostics | 2026-12-31 |
| NCT07928453Neuromed IRCCSCardiovascular And Dementia Risk in diabeTes: the Role of Nox2- Related Oxidative Stress. | 2027-01 |
Add all 12 to your calendar (.ics) → With an account.
Among the 92 studies in Dementia with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Dementia, in its various forms, is characterized by a generalized cognitive decline that can significantly compromise personal autonomy and quality of life. Mild Cognitive Impairment (MCI), although not classified as an overt form of dementia, represents a condition at evolutionary risk and is considered a crucial transitional stage for the early detection of cognitive decline. Understanding the impact of dementia and MCI from a multidimensional perspective is now essential to fully grasp the repercussions of these conditions on patients' daily lives. The present protocol aims to investigate key aspects related to these disorders, with the objective of exploring cognitive functioning, the degree of impairment in activities of daily living, and the presence of neuropsychiatric symptoms. Through an integrated and multidisciplinary approach, the study seeks to enhance clinical management and patient care, promoting more effective, targeted, and personalized interventions.
The present protocol aims to evaluate several fundamental aspects related to dementia and Mild Cognitive Impairment (MCI). Specifically, the objective is to investigate cognitive functioning, the degree of impairment in autonomy in activities of daily living, and the presence of neuropsychiatric and mood disorders. Through this integrated perspective, the study seeks to promote improvements in clinical management and patient care, fostering more effective and personalized interventions. The primary objective of the study is to assess the level of functional autonomy in individuals affected by dementia or Mild Cognitive Impairment (MCI), with particular attention to both basic and instrumental activities of daily living, using the ADL and IADL scales. In addition to the main goal, the study aims to analyze the presence and extent of emotional and neuropsychiatric symptoms and to evaluate their impact on the overall psychological well-being of patients, using standardized psychometric tools that will be described in detail in later sections.
The study has an observational, retrospective design. Data will be collected from the neuropsychological assessments of patients who have undergone at least three testing sessions, approximately 12 months apart, at the Neuropsychology Outpatient Clinic of the IRCCS Centro Neurolesi Bonino Pulejo.
The sample size estimation was conducted in relation to the primary objective-evaluating the level of functional autonomy impairment in patients diagnosed with dementia or MCI, measured using the ADL and IADL scales. It was hypothesized that a mean difference of at least 1 point on the IADL scale between the two groups (patients with dementia vs. patients with MCI) would be clinically significant, assuming a standard deviation of 1.5, based on literature and clinical practice data. The statistical power was calculated using the G*Power software (version 3.1), selecting a two-tailed independent-samples t-test. Assuming an effect size (d) of 0.5, a significance level (α) of 0.05, and a statistical power (1-β) of 80%, the calculation indicated that at least 64 participants per group (MCI and dementia) would be required, for a total of 128 participants. Considering a potential dropout or loss to follow-up rate of 15%, an overall recruitment target of approximately 151 patients has been set. Participants will be recruited from the Neuropsychology Outpatient Clinic of the IRCCS Centro Neurolesi Bonino Pulejo in Messina.
Participants will be included in the study if, based on the available clinical documentation, they meet the following criteria:
Participants will be excluded from the study if, based on clinical record review, they meet any of the following conditions:
The study involves retrospective collection of clinical and functional data from patients diagnosed with dementia or Mild Cognitive Impairment (MCI). Data from standardized tests will be extracted and analyzed from the medical records and databases available at the Neuropsychology Outpatient Clinic of the IRCCS Centro Neurolesi Bonino Pulejo in Messina, without any direct interventions involving the patients. Data will be entered into a secure database accessible only to study collaborators via personal credentials.
The following data will be collected:
Results from psychological, neuropsychological, and clinical tests administered during visits, including:
151
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
none - observational study
Dementia or Mild Cognitive Impairment (MCI) with ADL
The primary outcome variable considered for calculation is the score of the Activities of Daily Living (ADL) scale, used as the main index of functional autonomy in subjects with dementia or mild cognitive impairment (MCI).
Time frame: 12 MONTHS
Functional autonomy in instrumental activities measured with the Instrumental Activities of Daily Living (IADL) scale
Assessment of functional autonomy in instrumental activities of daily living in subjects with dementia or mild cognitive impairment (MCI) using the Instrumental Activities of Daily Living (IADL) scale.
Time frame: 12 MONTHS
Plan to share: No
Start is estimated for Dec 2025; primary completion for Dec 2026, 12 months later.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
IRCCS Centro Neurolesi Bonino Pulejo